Recent Company News

• 11:12 PM ET May 06, 2025
  

  Alterity Therapeutics to present phase 2 data for ATH434 for multiple system atrophy at International MSA Congress (A$0.01, 0.00)

• 09:55 PM ET Apr 09, 2025
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 06:59 PM ET May 04, 2025
  

  Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434 to treat multiple system atrophy (A$0.01, 0.00)

• 07:33 PM ET Apr 29, 2025
  

  Alterity Therapeutics reports Q3 net cash from / (used in) operating activities (A$726K) - Appendix 4C (A$0.01, 0.00)

• 08:25 AM ET Apr 28, 2025
  

  Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium (A$0.01, 0.00)

• 12:01 AM ET Apr 10, 2025
  

  Alterity Therapeutics publishes presentation in connection with Phase 2 Study of ATH434 in MSA (A$0.01, 0.00)

• 08:19 PM ET Apr 09, 2025
  

  Alterity Therapeutics presents new data from ATH434 Phase 2 Trial in MSA at AAN (A$0.01, 0.00)